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SerBACKGROUND Although previous observational studies have documented late luminal enlargement and
expansive remodeling following implantation of a bioresorbable vascular scaffold (BVS), no comparison with
metallic stents has been conducted in a randomized fashion.
OBJECTIVES This study sought to compare vessel remodeling patterns after either Absorb BVS or Xience metallic
drug-eluting stent (DES) implantation (Abbott Vascular, Santa Clara, California) and determine the independent
predictors of remodeling.
METHODS In the ABSORB II randomized trial, 383 lesions (n ¼ 359) were investigated by intravenous ultrasound both
post-procedure and at 3-year follow-up. According to vessel and lumen area changes over 3 years, we categorized
9 patterns of vessel remodeling that were beyond the reproducibility of lumen and vessel area measurements.
RESULTS The relative change in mean vessel area was signiﬁcantly greater with the BVS compared to the DES (6.7 
12.6% vs. 2.9  11.5%; p ¼ 0.003); the relative change in mean lumen area was signiﬁcantly different between the
2 arms (1.4  19.1% vs. 1.9  10.5%, respectively; p ¼ 0.031). Multivariate analysis indicated that use of the
BVS, female sex, balloon-artery ratio >1.25, expansion index $0.8, previous percutaneous coronary intervention, and
higher level of low-density lipoprotein cholesterol were independent predictors of expansive remodeling. Furthermore,
in the BVS arm, necrotic core pre-procedure was an independent determinant of expansive remodeling.
CONCLUSIONS Expansive vessel wall remodeling was more frequent and intense with the BVS than the metallic DES
and could be determined by patient baseline characteristics and periprocedural factors. The clinical effect of the
observed lumen and vessel remodeling must be investigated in further large clinical studies to optimize the clinical outcome
of patients and lesions treated by bioresorbable scaffolds. (ABSORB II Randomized Controlled Trial; NCT01425281)
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AB BR E V I A T I O N S
AND ACRONYM S
BVS = bioresorbable vascular
scaffold(s)
DES = drug-eluting stent(s)
IVUS = intravascular
ultrasound
LA = lumen area
PCI = percutaneous coronary
intervention
VA = vessel area
VH = virtual histology
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61I ntravascular ultrasound (IVUS) has been instru-mental in the understanding of the atheroscle-rotic process and in the development of
coronary interventional cardiology (1). Basically,
IVUS deﬁnes 2 interfaces: 1) one between the ﬂowing
blood and the intima; and 2) one between the media
and the adventitia. Therefore, multiple options of
interaction exist among these 3 compartments, lumen,
plaque-media, and adventitia. The relationship be-
tween lumen area (LA), plaque-media, and vessel
area (VA) is the foundation of Glagov’s principle of
compensatory expansive remodeling of the external
elastic membrane (2). Considering the changes in
these 3 compartments, there are, conceptually, 9 pos-
sibilities of expansive or constrictive remodeling,
increase or decrease in plaque-media, and increase or
decrease in LA (3). Fundamental to atherosclerosis
progression and regression, these interactions are
also essential as vessel wall reactions to the transient
barotrauma of balloon angioplasty (4–7) and the per-
manent or transient “scaffolding” effect of either
metallic stents (8) or bioresorbable scaffolds (9).SEE PAGE 75The advent of bioresorbable vascular scaffolds
(BVS) has prompted us to analyze the short- and long-
term effect of the bioresorbable scaffolds on vessel
wall dynamics, including remodeling (10). It has been
hypothesized that the potential for remodeling
should be more prominent than the remodeling
observed with metallic stents and should lead to late
lumen enlargement (11). The ABSORB II trial did not
meet its coprimary endpoints: superiority in vaso-
motion and noninferiority in angiographic late
luminal loss following implantation of the Absorb
drug-eluting BVS compared with the Xience metallic
drug-eluting stent (DES) (Abbott Vascular, Santa
Clara, California), but it has given us the opportunity
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METHODS
The ABSORB II trial was a prospective, single-
blind, multicenter clinical trial that random-
ized patients to percutaneous coronary
intervention (PCI) with placement of either
Absorb bioresorbable scaffolds or Xience
metallic stents in a 2:1 fashion. The trial
design, the study devices, and the inclusion
and exclusion criteria have been described in detail
previously (12,13). As mandated by the protocol, all
patients underwent documentary grayscale IVUS
and backscattered radiofrequency (virtual histology
[VH]) assessment before and after device implanta-
tion, as well as at 3-year follow-up. Clinical visits
and blood sample analysis, including low-density
lipoprotein cholesterol (LDL-C), were performed at
30 and 180 days and at 1, 2, and 3 years after the index
procedure. The blood samples were analyzed by a
central laboratory.
IVUS IMAGE ACQUISITION AND ANALYSIS. IVUS
data were acquired with a 3.2-F, 45 MHz rotational
IVUS catheter (Revolution 45 MHz, Volcano Corpora-
tion, Rancho Cordova, California) after intracoronary
injection of 200 mg of nitroglycerin, at a pullback
speed of 0.5 mm/s and a frame speed of 30 frames/s.
All pullbacks were analyzed ofﬂine at 1-mm longitu-
dinal intervals by an independent core laboratory
(Cardialysis BV, Rotterdam, the Netherlands) using
commercially available software (QIvus version 2.2,
Medis, Leiden, the Netherlands).
The methods of quantitative IVUS have been
previously published (1,12). Considering the difﬁculty
in measuring neointima in the biodegraded scaffold
at 3 years, to better compare the 2 devices, thescular. Dr. Baumbach has received research support
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CENTRAL ILLUSTRATION Patterns of Vessel Remodeling
Serruys, P.W. et al. J Am Coll Cardiol. 2017;70(1):60–74.
Relative changes in vessel area (VA) (constrictive remodeling <12%, expansive remodeling >þ12%) and relative changes in lumen area (LA)
(lumen reduction <15%, lumen enlargement >þ15%) deﬁned remodeling patterns. No lesions showed constrictive remodeling with LA
increase or expansive remodeling with LA decrease. Expansive vessel wall remodeling was more frequent with the bioresorbable vascular
scaffold (BVS) than the metallic drug-eluting stent (DES) and could be determined by patient baseline characteristics and periprocedural
factors. LDL ¼ low-density lipoprotein; PCI ¼ percutaneous coronary intervention.
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62intrascaffold-stent neointima was included in the
metric “plaque-media ¼ vessel area  lumen area.”
The reference segments after device implantation
were the 5-mm segments proximal and distal to thedevice. According to a previous study (14), relative
range of interobserver reproducibility of measure-
ment for lumen, plaque-media, and vessel cross-
sectional areas based on 2 SD of their measurements
FIGURE 1 Study Flow
501 patients in the study population
335 patients assigned to the Absorb group
364 lesions treated
329 pre-implantation and 330 post-implantation IVUS
318 paired IVUS measurements
311 pre-implantation IVUS-VH
313 patients had a 3 year clinical follow-up
266 lesions had follow-up IVUS (including 11 pre-TLR
IVUS carried forward*)
247 post-3Y paired IVUS measurements with 224 pre-
procedural IVUS-VH available
237 complete sets of pre-, post-, 3Y IVUS
155 patients had a 3 year clinical follow-up
140 lesions had follow-up IVUS (including 5 pre-TLR IVUS
carried forward*)
136 post-3Y paired IVUS measurements with 123 pre-
procedural IVUS-VH available
129 complete sets of pre-, post-, 3Y IVUS
22 patients excluded in total
4 patients withdrew consent after a clinical event
7 patients withdrew consent without a clinical event
1 patient withdrawn by physician without a clinical event
2 patients were lost to follow-up
8 patients died
11 patients excluded in total
5 patients withdrew consent without a clinical event
6 patients died
166 patients assigned to the Xience group
182 lesions treated
169 pre-implantation and 176 post-implantation IVUS
167 paired IVUS measurements
160 pre-implantation IVUS-VH
*The results of 18 pre–target lesion revascularization (TLR) intravascular ultrasound (IVUS) were carried forward to 3-year follow-up (3Y) for statistical
purposes. VH ¼ virtual histology.
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63were 15%, 22%, and 12%, respectively. Specif-
ically, expansive remodeling was deﬁned as a relative
change in mean VA >þ12%, while constrictive
remodeling was deﬁned as a relative change in mean
VA <12%. According to these relative values of
reproducibility, there were 9 theoretical patterns of
vessel-lumen-plaque remodeling based on increase,
no change, and decrease in each of the 3 parameters
(Central Illustration) (3).
The pre-procedure target (“to-be-scaffolded/
stented”) segments were deﬁned by coregistration
with post-procedural IVUS using identical landmarks,
such as side branches and calcium locations. Match-
ing was done using dedicated software (IvusOCT-
Registration, Division of Image Processing, Leiden,
the Netherlands) (15). Pre-procedural IVUS-VH anal-
ysis was performed within the target segments.
Tissue compositions, derived from pre-procedural
IVUS-VH analysis, were expressed in percentages,
averaged for multiple plaque-media cross-sectional
areas, and related to the different patterns of
remodeling at follow-up (16).Pre-procedural ofﬂine or online qualitative
comparative analysis (QCA) for the sizing of the
device was mandatory. The strategy of device
deployment, with or without post-dilation, is
described in detail in the protocol as well as the
various parameters involved in device deployment
(Online Appendix). The maximal diameter of the
device/post-dilation balloon throughout the proced-
ure was used for calculation of various balloon-artery
ratios, with reference lumen diameter deﬁned either
by IVUS using a circular model, as the average of
5-mm segments proximal and distal to the device
segment (17), or by QCA using the interpolated
method (Online Table 1).
The deﬁnitions of expansion index, asymmetry
index, eccentricity index, and deployment index are
reported in the Online Appendix (15,18–20).
OVERALL SUBSTUDY OBJECTIVES. The primary
objective of this study was to elucidate differences in
remodeling patterns following BVS or DES implanta-
tion. First, differences in mean lumen, vessel, and
plaque area changes were to be documented and the
TABLE 1 Baseline Characteristics, Pre-Procedural IVUS Findings, and Procedural Data*
BVS DES p Value
Patient characteristics
n 233 126
Age, yrs 61  10 60  10 0.223
Male 172 (73.8) 103 (81.7) 0.09
Current smoking 58 (24.9) 29 (23.0) 0.692
Hypertension requiring medication 148 (63.5) 80 (63.5) 0.996
Dyslipidemia requiring medication 167 (71.7) 90 (71.4) 0.961
Diabetes 50 (21.5) 28 (22.2) 0.867
Unstable angina 41 (17.6) 29 (23.0) 0.216
Prior MI 64 (27.7) 37 (29.4) 0.739
Previous PCI 80 (32.4) 45 (33.1) 0.889
Serum creatinine, mmol/l 80.8  17.6 82.2  19.2 0.484
BMI $30 kg/m2 61 (26.2) 36 (28.6) 0.626
Lesions
n 247 136
Lesion location 0.577
Right coronary artery 67 (27.1) 41 (30.1)
Left anterior descending 112 (45.3) 64 (47.1)
Left circumﬂex artery 68 (27.5) 31 (22.8)
Lesion classiﬁcation 0.235
A 3 (1.2) 0 (0.0)
B1 138 (55.9) 71 (52.2)
B2 103 (41.7) 65 (47.8)
C 3 (1.2) 0 (0.0)
Continued on the next page
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64various patterns of remodeling established. Second,
exploratory analysis of remodeling predictors, such
as tissue composition analyzed by IVUS-VH and
balloon-artery ratio, was performed. Finally, inde-
pendent predictors for expansive remodeling were
determined from multivariate analysis.
STATISTICAL ANALYSIS. Categorical variables are
presented as counts and percentages. Continuous
variables are presented as mean  SD or median
(interquartile range), as appropriate. A p
value <0.05 was considered statistically signiﬁcant.
Categorical variables were compared using chi-
square statistics or Fisher exact test. Continuous
variables between post-procedure and 3-year follow-
up were compared with paired Student t test, and
those between groups were compared with inde-
pendent Student t test or analysis of variance with
application of Bonferroni correction. In case of
target lesion revascularization, the IVUS documen-
tation prior to the treatment was carried forward
and included in the statistical analysis of the 3-year
results. The Pearson correlation coefﬁcient was used
to evaluate the strength and direction of the linear
relationship between 2 parameters. Receiver-
operating characteristic (ROC) analyses were per-
formed to compare diagnostic ability, and Youdenindex was used to derive the cutoff point. Multi-
variate logistic regression analysis was performed to
ﬁnd independent determinants of vessel remodel-
ing. The models were constructed using signiﬁcant
variables (p < 0.05) of univariate analyses. Statisti-
cal analyses were performed with SPSS version
24.0.0.1 (IBM, Armonk, New York).
RESULTS
In the ABSORB II trial, of 546 lesions (n ¼ 501)
analyzed at baseline, 247 lesions (n ¼ 233) in the BVS
arm and 136 lesions (n ¼ 126) in the DES arm had both
post-procedure and 3-year follow-up IVUS images
(Figure 1). Among lesions with paired post-procedure
and 3-year follow-up IVUS, pre-procedural IVUS was
available for 237 lesions in the BVS arm and 129
lesions in the DES arm, whereas pre-procedural
IVUS-VH was available in 224 and 123 lesions,
respectively. Baseline clinical, lesion, and procedural
characteristics in patients and lesions with paired
post-procedural and 3-year IVUS were well balanced
between both arms (Table 1). In terms of procedural
characteristics, the maximal pressure during device
implantation or post-dilation, nominal and expected
diameter of post-dilation balloon, and measured
diameter of device and post-dilation balloon were
signiﬁcantly higher in the DES arm than in the BVS
arm.
The absolute and relative changes in mean LA,
plaque-media area, and VA between post-procedure
and 3-year follow-up are tabulated in Table 2 (IVUS
parameters post-procedure and at 3-year follow-up
are provided in Online Table 2). The relative
changes in mean VA, LA, and plaque-media area were
signiﬁcantly different for the 2 arms (Figure 2).
The relationship between relative changes in mean
LA and mean VA is illustrated in Figure 3. To facilitate
the understanding of complex relationships among
relative changes of mean vessel, lumen, and plaque
area, 3-dimensional scatter plots were created (mov-
ing images are available in Online Videos 1 and 2).
There was a signiﬁcant positive correlation between
the changes in mean VA and mean LA both for the
BVS (correlation coefﬁcient [CC]: 0.767; 95%
conﬁdence interval [CI]: 0.711 to 0.813; p < 0.001;
y ¼ 1.17  6.42; R2 ¼ 0.589) and for the DES pop-
ulations (CC: 0.663; 95% CI: 0.557 to 0.747; p < 0.001;
y ¼ 0.61  3.65; R2 ¼ 0.440); however, the distri-
bution in the relative changes in mean VA and mean
LA in the BVS arm was more outstretched than the
changes observed with DES (p ¼ 0.0466; Fisher r-to-z
transformation).
TABLE 1 Continued
BVS DES p Value
Pre-procedural IVUS ﬁndings
Available lesions 237 129
Mean vessel area, mm2 11.42  3.43 12.35  3.22 0.01
Mean lumen area, mm2 4.81  1.41 5.02  1.38 0.158
Mean plaque area, mm2 6.61  2.49 7.32  2.41 0.008
Mean plaque burden, % 56.98  8.57 58.57  8.49 0.088
Minimum vessel area, mm2 8.59  3.11 9.47  3.03 0.009
Minimum lumen area, mm2 2.01  0.71 2.11  0.79 0.269
Reference vessel area, mm2 11.78  3.84 12.74  3.53 0.016
Procedural details
Lesions 247 136
Pre-dilation performed 247 (100.0) 134 (98.5) 0.125
Nominal diameter of pre-dilation
balloon, mm
2.61  0.36 2.64  0.36 0.347
Maximal pressure during pre-dilation,
atm
12.16  3.00 12.34  3.01 0.574
Nominal diameter of device, mm 3.02  0.31 3.06  0.28 0.191
Length of implanted device, mm 23.60  10.50 23.28  8.79 0.766
Maximal pressure during device
implantation, atm
13.26  2.74 13.89  2.62 0.03
Expected device diameter, mm 3.34  0.34 3.28  0.33 0.109
Mean diameter of device balloon
measured by QCA, mm
2.71  0.36 2.94  0.33 <0.001
Minimal diameter of device balloon
measured by QCA, mm
2.37  0.38 2.63  0.35 <0.001
Post-dilation performed 150 (60.7) 82 (60.3) 0.934
Nominal diameter of post-dilation
balloon, mm
3.16  0.33 3.27  0.36 0.016
Maximal pressure during post-dilation,
atm
15.26  3.04 16.88  3.39 <0.001
Expected diameter of post-dilation
balloon, mm
3.26  0.34 3.39  0.37 0.007
Mean diameter of post-dilation
balloon measured by QCA, mm
2.64  0.30 2.99  0.32 <0.001
Minimal diameter of post-dilation
balloon measured by QCA, mm
2.41  0.32 2.75  0.32 <0.001
Maximal† mean balloon diameter
throughout procedure measured
by QCA, mm
2.75  0.33 3.00  0.34 <0.001
Maximal† mean balloon diameter
throughout procedure measured
by QCA, mm
2.46  0.34 2.73  0.36 <0.001
Post-procedural patient-related factors
n 233 126
Mean LDL-C, mmol/l 2.32  0.63 2.29  0.59 0.653
Values are n, mean  SD, or n (%). *Tabulated values differ from the primary report (13) because the population
consisted exclusively of patients and lesions with paired IVUS measurements post-procedure and at 3-year
follow-up. †Maximal diameter throughout procedure.
BMI ¼ body mass index; BVS ¼ bioresorbable vascular scaffold; DES ¼ drug-eluting stent; IVUS ¼ intravascular
ultrasound; LDL-C ¼ low-density lipoprotein cholesterol; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention; QCA ¼ qualitative comparative analysis.
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65Based on the boundaries of interobserver repro-
ducibility of area measurements, we categorized 9
patterns of remodeling per relative changes in mean
LA and mean VA (Central Illustration, Figure 3). The
IVUS parameters post-procedure and at 3 years within
each group are provided in Online Table 3.
The lesion subset groups are labeled A through I
(Figure 3). In the BVS arm, groups B and C showed an
increase in mean LA that was beyond interobserver
reproducibility. In group B, the increase in mean LA
was partially due to a small decrease in plaque-media
area and plaque burden. Group C consisted of cases
with late lumen enlargement associated with expan-
sive remodeling that exceeded the increase in plaque-
media area, resulting in a plaque burden decrease.
Group E, with the largest number of observations,
consisted of lesions that did not show any change
beyond the interobserver reproducibility for VA and
LA measurements. Group F displayed an increase in
plaque-media, which was largely compensated by
an expansive remodeling of the vessel, so that the
lumen area showed minor changes, but plaque
burden increased. Group G exhibited a decrease in
mean LA mainly resulting from constrictive remod-
eling. Finally, group H comprised lesions with a
decrease in mean LA resulting from an increase in
mean plaque-media area, not compensated by
expansive remodeling.
In the DES arm (Figure 3), the large majority of
lesions (group E) did not exhibit any change in LA
or VA beyond the interobserver reproducibility. The
second group in terms of number (group F) was
represented by stented lesions that exhibited some
degree of VA increase without LA decrease (no
intrastent neointimal hyperplasia). Group H was
characterized by an LA decrease due to an increase
in intrastent neointima not associated with VA
increase. The other groups contained fewer than 5
patients.
In both arms, there were no patients with expan-
sive remodeling and a decrease in lumen dimensions
or constrictive remodeling with an increase in lumen
dimensions (group A or I). In comparing proportions
of each remodeling subset in the 2 arms (Table 3),
expansive remodeling and either lumen enlargement
or lumen reduction were more frequent in the BVS
arm versus the DES arm, whereas frequency of
constrictive remodeling did not differ. Late acquired
malapposition was documented in 6 lesions of the
BVS arm and was associated with LA increase (Online
Table 4). One late acquired malapposition was
observed in BVS group E.
Proportions of pre-procedural VH composition
(average percentage of each tissue component inplaque-media areas) according to vessel remodeling
patterns at follow-up are shown in Table 4 and
Figure 4. In the BVS arm, there were no signiﬁcant
differences in the proportion of ﬁbrous, ﬁbrofatty
tissue and dense calcium between the various vessel
remodeling patterns; the proportion with a necrotic
core was signiﬁcantly less in the constrictive remod-
eling group, but was higher in the expansive
TABLE 2 IVUS Parameters
BVS (n ¼ 247) DES (n ¼ 136) p Value
Absolute change
Mean VA, mm2 0.75  1.66 0.31  1.29 0.004
Mean LA, mm2 0.07  1.20 0.15  0.70 0.02
Mean plaque area, mm2 0.67  1.01 0.46  1.01 0.047
Mean plaque burden, % 2.68  5.58 2.29  4.24 0.451
Relative change
Mean VA, % 6.7  12.6 2.9  11.5 0.003
Mean LA, % 1.4  19.1 1.9  10.5 0.031
Mean plaque area, % 12.4  16.0 8.5  18.9 0.042
Mean plaque burden, % 5.6  11.2 5.0  8.9 0.572
Values are mean  SD.
LA ¼ lumen area; VA ¼ vessel area; other abbreviations as in Table 1.
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66remodeling group than in the group without vessel
remodeling. In the DES arm, there were no signiﬁcant
differences in IVUS-VH composition for each remod-
eling group. ROC analysis of the proportion of
necrotic core that predicted expansive remodeling in
the BVS cases showed an area under the curve of 0.63FIGURE 2 Mean Area Changes
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Signiﬁcant absolute and relative area changes on IVUS were seen betwe
VA ¼ vessel area; other abbreviations as in Figure 1.(95% CI: 0.55 to 0.71; p ¼ 0.004) with a cutoff value of
16.7% (sensitivity 61.0%, speciﬁcity 61.8%). ROC
analysis performed in the DES group did not show
signiﬁcance (p ¼ 0.255).
The nominal, expected, or measured value of the
maximal balloon diameter and balloon-artery ratios
for the 3 categories of vessel remodeling (constrictive,
no change in VA, expansive) are shown in Table 5 and
Figure 5. Overall, the balloon diameters, either nom-
inal or expected or measured by QCA (mean or mini-
mal), failed to show any relationships with the
development of constrictive or expansive remodeling
in either group. However, increased balloon-artery
ratios were associated with expansive remodeling
in the BVS arm, in particular when nominal and
expected balloon-artery ratios were used; only the
QCA-measured balloon-artery ratio was associated
with expansive remodeling in the DES arm.
The ROC analysis of expected balloon-artery ratio,
among other balloon-artery ratios, showed the largest
area under the curve (0.69; 95% CI: 0.61 to 0.77;
p < 0.001) with a cutoff point of 1.25 (sensitivityp = 0.003
p = 0.031
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A. Constrictive remodeling with late lumen enlargement
B. Plaque media decrease with late lumen enlargement
C. Expansive remodeling with late lumen enlargement
D. Constrictive remodeling with plaque/media reduction
E. Within the reproducibility of the measurement
F. Expansive remodeling with plaque/media increase
G. Constrictive remodeling with late lumen reduction
H. Plaque/media increase with late lumen reduction
I. Expansive remodeling with late lumen reduction
0 (0)
17 (6.9)
40 (16.2)
2 (0.8)
100 (40.5)
31 (12.6)
10 (4.0)
47 (19)
0 (0)
Absorb (n = 247) Xience (n = 136) P value*
0 (0)
2 (1.5)
4 (2.9)
3 (2.2)
106 (77.9)
12 (8.8)
3 (2.2)
6 (4.4)
0 (0)
-
0.020
<0.001
0.352
<0.001
0.269
0.395
<.0001
-
A total of 9 patterns of remodeling were characterized; reference lines indicate 12% relative change in mean VA and 15% relative change in mean LA (boundaries
for interobserver reproducibility). Data are counts (%). Absolute values in each group are tabulated in Online Table 3. To facilitate the understanding of complex
relationships among relative changes of mean vessel, lumen, and plaque area, 3-dimensional scatter plots were created (Online Videos 1 and 2). *p value for chi-square
test. Abbreviations as in Figure 2.
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6761.0%, speciﬁcity 75.3%) for prediction of expansive
remodeling in the BVS arm. ROC analysis of expected
balloon-artery ratio performed in the DES group did
not show signiﬁcance (p ¼ 0.174).
Predictors for expansive remodeling (n ¼ 87
lesions, 22.7%) were analyzed by multivariate
logistic regression analysis, whereas predictors for
constrictive remodeling were not investigated due to
the limited number of lesions with constrictive
remodeling (n ¼ 18 lesions, 4.7%). Online Table 5
shows the result of univariate analysis for predictors
of expansive remodeling. Subsequent multivariate
analysis (Table 6) identiﬁed that BVS implantation,female sex, balloon-artery ratio by maximal expected
diameter of balloon throughout procedure >1.25,
expansion index $0.8, previous PCI, and higher
mean LDL-C over 3 years were independent predictors
for expansive remodeling. When the multivariate
model was applied to the BVS population only, pre-
procedural proportion of necrotic core >16.7%
became signiﬁcant. The multivariate analysis of the
DES arm is not formally reported due to the small
number of lesions showing expansive remodeling (16
lesions, 11.8%). However, the effect of the device type
(p value for interaction) was not signiﬁcantly different
for each independent determinant of expansive
TABLE 3 Difference in Proportions of Mean VA and LA Changes*
BVS
(n ¼ 247)
DES
(n ¼ 136) p Value†
Expansive remodeling (C, F, I) 71 (28.7) 16 (11.8) <0.001
Constrictive remodeling (A, D, G) 12 (4.9) 6 (4.4) 0.843
Lumen enlargement (A, B, C) 57 (23.1) 6 (4.4) <0.001
Lumen reduction (G, H, I) 57 (23.1) 9 (6.6) <0.001
No signiﬁcant change in either VA or LA (E) 100 (40.5) 106 (77.9) <0.001
Values are n (%). *Letters correspond to subset designations in Figure 3. †Chi-square test.
Abbreviations as in Tables 1 and 2.
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68remodeling identiﬁed by the multivariate analysis,
despite some trends that might become signiﬁcant in a
larger sample size population (Figure 6).
DISCUSSION
In this study, the main ﬁndings were: 1) lesions
treated with the BVS exhibited a larger increase in4 Plaque Composition
ANOVA
p = 0.338
ANOVA
p < 0.001
*
‡
†
* p = 0.001, † p = 0.030, ‡ p = 0.018
ANOVA
p = 0.077
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p = 0.359
Fibrous Fibro
Fatty
Dense
Calcium
Necrotic
Core
Absorb (n = 224 Lesions)
8
7
6
5
4
3
2
1
Ar
ea
 (%
)
Constrictive remodeling Without vessel r
cedural plaque composition as analyzed by intravascular ultrasound-virtual h
030. ‡p ¼ 0.018. ANOVA ¼ analysis of variance.mean VA than DES-treated lesions; 2) scaffold im-
plantation, female sex, the maximal expected
balloon-artery ratio >1.25, expansion index $0.8,
previous PCI, and higher mean level of LDL-C
(average over 3 years) were independent factors pre-
dicting expansive remodeling; and 3) pre-procedural
greater proportion of necrotic core (threshold of
>16.7% in mean plaque area) was also an independent
predictor for expansive remodeling, especially in the
BVS arm.
At a single time point in a post-mortem study, Gla-
gov et al. (2) reported that the LA was not decreased in
relation to any plaque burden increase for values be-
tween 0% and 40%, but beyond that threshold, the
compensatory expansive remodeling was no longer
operational. In fact, very few lesions investigated in
the present study had plaque burden <40% (Online
Table 2); however, the relationship between LA and
plaque burden >40% was consistent with Glagov’s
theorem (Figure 7). In our serial analysis, taking intoANOVA
p = 0.924
ANOVA
p = 0.322
ANOVA
p = 0.761
ANOVA
p = 0.736
Xience (n = 123 Lesions)
0
0
0
0
0
0
0
0
0
Fibrous Fibro
Fatty
Dense
Calcium
Necrotic
Core
emodeling Expansive remodeling
istology is seen in 3 categories of vessel remodeling. *p ¼ 0.001.
TABLE 4 Plaque Composition of Mean Plaque Cross-Sectional Area
Constrictive
Remodeling
Without Vessel
Remodeling
Expansive
Remodeling p Value*
BVS
n 12 153 59
Fibrous tissue, % 36.6  12.9 31.9  11.3 31.4  11.1 0.338
Fibrofatty, % 50.6  15.6 47.6  17.2 44.5  16.6 0.359
Dense calcium, % 2.2  2.7 4.8  4.7 5.6  5.2 0.077
Necrotic core, % 10.5  6.2 15.7  6.7 18.5  6.5 <0.001
DES
n 4 105 14
Fibrous tissue, % 32.6  7.1 30.5  11.2 30  14 0.924
Fibrofatty, % 45.6  21.6 49.8  15.3 47.1  16.6 0.736
Dense calcium, % 4.6  4.6 4.3  3.6 5.1  4.9 0.761
Necrotic core, % 17.2  10.9 15.3  5.8 17.8  6.6 0.322
Values are n or mean  SD. *p value for analysis of variance (ANOVA).
Abbreviations as in Table 1.
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69account the measurement variability of the plaque
burden metrics, true plaque burden regression could
not be documented in both arms, whereas plaque
burden increase was observed in 12.1% in the BVS arm
and 4.5% in the DES arm. However, the slope of the
relationship between plaque burden and LAwas 2-fold
steeper in the scaffold arm (0.16) when compared to
the DES arm (0.08), exemplifying the remodeling
capability of the scaffolds.
VASCULAR RESPONSE AFTER INTERVENTION AND
FUNCTION OF SCAFFOLDING. In the era of balloon
angioplasty, restenosis was caused mainly by
constrictive remodeling (4). In a study using serial
IVUS after angioplasty or directional coronary athe-
rectomy, expansive remodeling was observed up to
1 month, but luminal reduction prevailed from 1 to
6 months, mainly due to negative remodeling (5,6).
Between 6 months and 5 years, most patients have
luminal enlargement after balloon angioplasty (7).
Bare-metal stents were found to prevent
constrictive remodeling, but generated intrastentTABLE 5 Balloon Diameters and Balloon-Artery Ratios
Cases With
Parameter Available
BVS (n ¼ 247)
Maximal nominal balloon diameter, mm 247
Maximal expected balloon diameter, mm 247
Maximal mean balloon diameter measured
by QCA, mm
240
Maximal minimal balloon diameter measured
by QCA, mm
240
Balloon-artery ratio by maximal nominal
balloon diameter
209
Balloon-artery ratio by maximal expected
balloon diameter
209
Balloon-artery ratio by maximal mean balloon
diameter measured by QCA
239
Balloon-artery ratio by maximal MLD of balloon
measured by QCA
239
DES (n ¼ 136)
Maximal nominal balloon diameter, mm 136
Maximal expected balloon diameter, mm 136
Maximal mean balloon diameter measured
by QCA, mm
136
Maximal minimal balloon diameter measured by
QCA, mm
136
Balloon-artery ratio by maximal nominal
balloon diameter
116
Balloon-artery ratio by maximal expected
balloon diameter
116
Balloon-artery ratio by maximal mean balloon
diameter measured by QCA
134
Balloon-artery ratio by maximal MLD of balloon
measured by QCA
134
Values are n or mean  SD. *p value for ANOVA.
MLD ¼ minimal lumen diameter; QCA ¼ quantitative coronary angiography; other abbneointimal hyperplasia resulting in some cases of
in-stent restenosis (8). Antiproliferative drug-
eluting metallic stents are effective to reduce
intrastent neointimal hyperplasia (21). WithConstrictive
Remodeling
No Change
in VA
Expansive
Remodeling p Value*
3.08  0.27 3.11  0.33 3.10  0.32 0.951
3.43  0.36 3.36  0.33 3.41  0.34 0.504
2.84  0.26 2.75  0.35 2.74  0.32 0.626
2.59  0.25 2.45  0.35 2.45  0.35 0.381
0.99  0.10 1.08  0.14 1.17  0.17 <0.001
1.09  0.10 1.17  0.18 1.29  0.20 <0.001
1.02  0.14 1.06  0.13 1.08  0.10 0.313
0.93  0.12 0.94  0.13 0.96  0.11 0.638
3.04  0.19 3.19  0.34 3.05  0.29 0.194
3.09  0.32 3.28  0.35 3.27  0.40 0.423
2.77  0.20 3.02  0.34 2.94  0.37 0.158
2.52  0.20 2.74  0.36 2.70  0.35 0.315
1.10  0.06 1.10  0.15 1.13  0.14 0.818
1.11  0.12 1.13  0.18 1.21  0.23 0.326
1.09  0.12 1.15  0.14 1.24  0.16 0.041
1.00  0.11 1.04  0.13 1.13  0.14 0.027
reviations as in Tables 1, 2, and 4.
FIGURE 5 Balloon-Artery Ratios
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Balloon-artery ratios are shown for 3 categories of vessel remodeling. ANOVA ¼ analysis of variance; QCA ¼ quantitative coronary angiography.
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70early-generation DES, positive remodeling leading
to late acquired malapposition could occur, whereas
this phenomenon is almost absent in newer-
generation DES (22).
Drug-eluting bioresorbable scaffolds prevent
constrictive remodeling in the ﬁrst 6 months
following implantation, but after the loss of their
mechanical integrity, they allow expansive remodel-
ing modulated by predictors described in the
following text (23–25).
In contrast to the current study, the mean LA
observed by optical coherent tomography in ABSORB
cohort B at 3 years was stable after the initial decrease
at 6 months (10). However, due to the shorter pene-
tration depth, optical coherent tomography could not
evaluate VA and remodeling as IVUS was able to in
this study.
PREDICTORS FOR EXPANSIVE REMODELING. In the
present study, BVS implantation was an indepen-
dent predictor for expansive remodeling. Inprevious observational studies, it has been docu-
mented that the mechanical support of scaffolds is
lost 6 to 12 months after implantation (23) and that
vessel and scaffold can potentially enlarge subse-
quently. In the preclinical study by Otsuka et al.
(26), BVS implantation had a greater inﬂammation
score than the metallic stents studied here; the
scaffolds exhibited expansive remodeling 12 months
after implantation, which was paralleled by LA
enlargement, whereas metallic stents showed mini-
mal change in vessel size. Considering the interac-
tion between polymer degradation and
inﬂammatory response (27), polymer absorption
may promote inﬂammation and consecutive expan-
sive remodeling after BVS implantation. However,
the resorption of lactic acid is not a sole driver, if at
all. Loss in scaffold structures (late structural
discontinuity) and recovery of pulsatility might also
contribute to remodeling mediated by inﬂammation
(28,29) and may play a major role in late lumen
enlargement and vessel remodeling. Besides the
FIGURE 6 Interaction Analysis Between Remodeling Predictors and Device Type
Adjusted
odds ratio
Sex
Female
Male
Previous PCI
No
Yes
Expected balloon-artery ratio
>1.25
≤1.25
Post-procedural IVUS:
expansion index
≥0.8
<0.8
Pre-procedural IVUS-VH:
necrotic core
>16.7
≤16.7
5.25 (0.94-29.30)
2.77 (0.89-8.61)
3.93 (1.15-13.46)
2.02 (0.50-8.16)
5.43 (1.02-29.03)
2.39 (0.75-7.67)
6.62 (1.36-32.17)
1.92 (0.61-6.04)
7.73 (1.77-33.74)
1.36 (0.40-4.67)
0.1
Xience better to
trigger expansive
remodeling
Absorb better to
trigger expansive
remodeling
1 10 100
0.636
0.653
0.173
0.720
0.135
p value for interaction
There was no signiﬁcant difference by device type for each determinant of expansive remodeling. PCI ¼ percutaneous coronary intervention; other abbreviations
as in Figure 1.
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71inﬂammatory response, another determinant of
remodeling might be shear stress, whose inﬂuence
is currently being investigated (30).
Female sex was also an independent predictor for
expansive remodeling in the current study. In an
IVUS substudy of the WISE (Women’s Ischemia
Syndrome Evaluation) study, there was a highTABLE 6 Multivariate Analysis: Predictors of Expansive Remodeling
O
Adjusted OR
Absorb implantation 2.85
Female 2.84
Balloon-artery ratio by maximal expected diameter
of balloon throughout procedure >1.25
2.45
Post-procedural IVUS: expansion index $0.80 2.44
Previous PCI 2.13
Mean LDL-C over 3 yrs, per mmol/l 2.10
Pre-procedural IVUS-VH: necrotic core >16.7% 1.64
Post-procedural IVUS: asymmetry index >0.30 1.49
Post-procedural IVUS: eccentricity index <0.70 1.21
Pre-procedural IVUS: mean LA, per mm2 0.97
Pre-procedural IVUS: mean VA, per mm2 0.90
CI ¼ conﬁdence interval; NA ¼ not available; OR ¼ odds ratio; VH ¼ virtual histology; oprevalence of atherosclerosis with positive remodel-
ing and preserved lumen size (31). Considering that
estrogen has anti-inﬂammatory effects, the pro-
inﬂammatory status after menopause might promote
expansive remodeling (32).
Among the balloon-artery ratios investigated, the
ratio calculated with the expected balloon diameterverall BVS
95% CI p Value Adjusted OR 95% CI p Value
1.16–6.96 0.022 NA
1.35–5.96 0.006 3.25 1.35–7.81 0.008
1.11–5.41 0.026 3.17 1.23–8.14 0.017
1.11–5.36 0.026 3.91 1.49–10.22 0.005
1.04–4.34 0.038 2.09 0.90–4.86 0.088
1.20–3.65 0.009 2.67 1.38–5.17 0.004
0.81–3.31 0.166 2.5 1.08–5.79 0.033
0.64–3.44 0.352 1.65 0.60–4.52 0.334
0.49–2.99 0.686 0.95 0.35–2.57 0.922
0.63–1.50 0.896 0.91 0.54–1.55 0.73
0.75–1.08 0.236 1.00 0.81–1.23 0.966
ther abbreviations as in Tables 1 and 2.
FIGURE 7 Relation Between Plaque Burden Change and Lumen Area
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Lesions with mean plaque burden $40% in both post-procedure and at 3-year follow-up were plotted. Lines representing reproducibility range of lumen area
(1.1 w þ1.1 mm2) and plaque burden (8.7 w þ8.7%) are superimposed (14). In plotting lesions with mean plaque burden $40% post-procedure and at 3-year
follow-up, a steeper slope with BVS denoted scaffold remodeling capability. *r ¼ Pearson’s correlation efﬁcient.
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72had the best predictive value, probably because the
parameter also incorporates the inﬂation pressure.
The expected balloon diameter concept has been
appropriately criticized because this parameter was
evaluated in vitro, in the absence of any constraining
force, such as a calciﬁed or ﬁbrotic wall; however, in
this study, the statistical analysis based on a
sensitivity-speciﬁcity indicator led us to discover that
an expected balloon-artery ratio >1.25 was an inde-
pendent procedural parameter predicting an expan-
sive remodeling process in a large-scale clinical
study. A high balloon-artery ratio resulted in vascular
injury, which has been reported to induce expansive
remodeling (33) through macrophage inﬁltration
and matrix metalloproteinase increase (34). Also, the
relationship between expansion index and vessel
remodeling must rely on the same pathophysiological
principle.
Higher LDL-C and necrotic core have previously
been reported as predictors of expansive remodel-
ing (35–37). Higher LDL-C level can increase necrotic
core, oxidize lipid pool in vessel walls, and
induce inﬂammatory responses involving metal-
loproteinases that promote vessel enlargement
(38,39). The concomitant presence of a pre-existing
inﬂammatory process (necrotic core) and the
inﬂammatory process speciﬁcally related to the
bioabsorption of the polymer may lead to longerand stronger inﬂammation-inducing expansive
remodeling (26,40).
STUDY LIMITATIONS. The major limitation of this
study is the intravascular character of the investi-
gation; whenever the IVUS catheter did not or could
not cross the scaffolded or stented area, IVUS data
for serial assessment were not available, which
could potentially bias the serial analysis of wall
dynamics. Of 32 patients who had repeat target
lesion revascularization, 18 had intravascular imag-
ing before repeat treatment of their target lesion,
whereas the remaining 14 were not assessed. The
expected balloon-artery ratio was only available in
325 of 383 lesions (84.9%) due to the lack of
IVUS-measured reference lumen diameter. The
univariate predictive value of necrotic core for
positive remodeling was weak according to the low
area under the curve. However, the identiﬁed
threshold emerged as an independent predictor in
the multivariate analysis in conjunction with other
parameters. Multivariate analyses for constrictive
remodeling could not be performed due to the
limited number of lesions. At the present stage, the
clinical signiﬁcance of (expansive) remodeling with
the BVS studied here is unclear due to the small
number of patients enrolled as well as the small
number of events reported.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Coronary lesions treated with bioresorbable
scaffolds more frequently exhibit expansive remodeling
than those treated with metallic stents. In addition,
patient characteristics and procedural factors such as
balloon-artery ratio and expansion index also inﬂuence
vessel remodeling.
TRANSLATIONAL OUTLOOK: Additional research is needed
to elucidate the relationship between dynamic vessel remodeling
and clinical outcomes in patients undergoing percutaneous
revascularization with these devices.
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73CONCLUSIONS
In the ABSORB II trial, BVS use showed frequent
dynamic vessel remodelingwith larger increase inmean
lumen and vessel area than the comparator DES. This
vessel remodeling was determined by patient baseline
characteristics and periprocedural factors including
balloon-artery ratio and expansion index. The clinical
effect of this observed lumen and vessel remodeling
requires investigation in further large clinical studies.
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